A detailed history of Black Rock Inc. transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 105,303 shares of DMAC stock, worth $561,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,303
Previous 103,370 1.87%
Holding current value
$561,264
Previous $286,000 8.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.16 - $3.66 $4,175 - $7,074
1,933 Added 1.87%
105,303 $310,000
Q1 2024

May 10, 2024

SELL
$2.58 - $3.23 $3,513 - $4,399
-1,362 Reduced 1.3%
103,370 $286,000
Q4 2023

Feb 13, 2024

BUY
$2.05 - $2.99 $6,164 - $8,990
3,007 Added 2.96%
104,732 $297,000
Q3 2023

Nov 13, 2023

BUY
$2.56 - $4.4 $76,313 - $131,164
29,810 Added 41.45%
101,725 $262,000
Q2 2023

Aug 11, 2023

BUY
$1.53 - $4.4 $374 - $1,078
245 Added 0.34%
71,915 $310,000
Q1 2023

May 12, 2023

BUY
$1.32 - $1.89 $2,287 - $3,275
1,733 Added 2.48%
71,670 $109,000
Q4 2022

Feb 13, 2023

BUY
$1.13 - $1.62 $1,205 - $1,728
1,067 Added 1.55%
69,937 $110,000
Q3 2022

Nov 14, 2022

BUY
$1.2 - $2.07 $2,583 - $4,456
2,153 Added 3.23%
68,870 $85,000
Q2 2022

Aug 12, 2022

BUY
$1.86 - $2.62 $19,117 - $26,928
10,278 Added 18.21%
66,717 $135,000
Q1 2022

May 12, 2022

SELL
$2.29 - $3.88 $4,884 - $8,276
-2,133 Reduced 3.64%
56,439 $141,000
Q4 2021

Feb 10, 2022

BUY
$3.43 - $4.65 $8,924 - $12,099
2,602 Added 4.65%
58,572 $219,000
Q3 2021

Nov 09, 2021

SELL
$3.1 - $4.32 $16,395 - $22,848
-5,289 Reduced 8.63%
55,970 $225,000
Q2 2021

Aug 11, 2021

BUY
$4.45 - $9.91 $272,602 - $607,076
61,259 New
61,259 $273,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $141M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.